BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25614211)

  • 1. Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in papillary thyroid carcinomas.
    Zhan XX; Zhao B; Diao C; Cao Y; Cheng RC
    Endocr Pathol; 2015 Mar; 26(1):21-6. PubMed ID: 25614211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
    Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
    Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms.
    Baldus SE; Hanisch FG; Kotlarek GM; Zirbes TK; Thiele J; Isenberg J; Karsten UR; Devine PL; Dienes HP
    Cancer; 1998 Mar; 82(6):1019-27. PubMed ID: 9506345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176).
    Andergassen U; Kölbl AC; Zebisch M; Heublein S; Hutter S; Ilmer M; Schindlbeck C; Friese K; Jeschke U
    Histol Histopathol; 2014 Jul; 29(7):913-23. PubMed ID: 24399516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro.
    Jeschke U; Richter DU; Hammer A; Briese V; Friese K; Karsten U
    Histochem Cell Biol; 2002 Mar; 117(3):219-26. PubMed ID: 11914919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
    Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
    Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
    Hao Y; Jin C; Wang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.
    Lin WM; Karsten U; Goletz S; Cheng RC; Cao Y
    Int J Exp Pathol; 2011 Apr; 92(2):97-105. PubMed ID: 21070402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression.
    Abrosimov A; Saenko V; Meirmanov S; Nakashima M; Rogounovitch T; Shkurko O; Lushnikov E; Mitsutake N; Namba H; Yamashita S
    Endocr Pathol; 2007; 18(2):68-75. PubMed ID: 17916995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.
    Wreesmann VB; Sieczka EM; Socci ND; Hezel M; Belbin TJ; Childs G; Patel SG; Patel KN; Tallini G; Prystowsky M; Shaha AR; Kraus D; Shah JP; Rao PH; Ghossein R; Singh B
    Cancer Res; 2004 Jun; 64(11):3780-9. PubMed ID: 15172984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of mucin-l and beta-catenin in papillary thyroid carcinoma and the clinical significance thereof].
    He F; Li H; Li WS; Dong XH
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):393-6. PubMed ID: 19567117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
    Mylonas I; Mayr D; Walzel H; Shabani N; Dian D; Kuhn C; Kunze S; Jeschke U; Friese K
    Anticancer Res; 2007; 27(4A):1975-80. PubMed ID: 17649808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.
    Morari EC; Silva JR; Guilhen AC; Cunha LL; Marcello MA; Soares FA; Vassallo J; Ward LS
    Endocr Pathol; 2010 Dec; 21(4):242-9. PubMed ID: 21057891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
    Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
    Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells.
    Cao Y; Merling A; Karsten U; Goletz S; Punzel M; Kraft R; Butschak G; Schwartz-Albiez R
    Int J Cancer; 2008 Jul; 123(1):89-99. PubMed ID: 18398838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors.
    Dragon AC; Beermann LM; Umland M; Bonifacius A; Malinconico C; Ruhl L; Kehler P; Gellert J; Weiß L; Mayer-Hain S; Zimmermann K; Riese S; Thol F; Beutel G; Maecker-Kolhoff B; Yamamoto F; Blasczyk R; Schambach A; Hust M; Hudecek M; Eiz-Vesper B
    Front Immunol; 2023; 14():1219165. PubMed ID: 37915564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
    Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
    Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
    Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
    Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
    Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
    Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.